As one of the founding members of Lykan Bioscience, and our CEO, Tony aims to revolutionize the Cell and Gene Therapy industry by bringing his expertise in value creation to Lykan’s Manufacturing Services OrganizationTM for Cell-Based Therapies.
A seasoned industry veteran with over 40 years of biologics manufacturing experience, Tony’s successes include turning top-heavy, inefficient operations into profitable organizations as well as multiple plant builds and successful acquisitions.
His experience spans both biopharmaceutical and contract manufacturing organizations such as WelGen, Pharmachem, Dendreon, Lonza/Cambrex, and Marathon Biopharmaceuticals.
While at Dendreon (2010), Mr. Rotunno was instrumental in recreating Dendreon’s Provenge® operations which included the startup, commissioning, and validation of two new facilities & reducing COGS by approximately 80% over a 5-year period.
At Marathon, Tony guided the team in launching the manufacturing operations for the first genetically engineered recombinant /transgenic (AtrynTM) moving the company from net losses to production of multiple generations of biologics, and generating $100 million in revenue.
What inspires Tony is the passion to be able to enable more and more patients to live better and longer lives, even if it’s one more day.